Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma
about
Novel agents for multiple myeloma to overcome resistance in phase III clinical trialsMithramycin exerts an anti-myeloma effect and displays anti-angiogenic effects through up-regulation of anti-angiogenic factorsGalectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myelomaLidamycin shows highly potent cytotoxic to myeloma cells and inhibits tumor growth in miceThymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma.Marine Natural Products as Inhibitors of Hypoxic Signaling in Tumors.Marine compounds inhibit growth of multiple myeloma in vitro and in vivoThe Aplidin analogs PM01215 and PM02781 inhibit angiogenesis in vitro and in vivo.Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximabMarine-derived angiogenesis inhibitors for cancer therapy.c-Jun N-terminal kinase phosphorylation is a biomarker of plitidepsin activity.CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin.Plitidepsin: design, development, and potential place in therapy.Development of target-specific treatments in multiple myeloma.Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma.Nano-encapsulation of plitidepsin: in vivo pharmacokinetics, biodistribution, and efficacy in a renal xenograft tumor model.Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers.
P2860
Q26822754-22FD4339-CEBA-48CC-9F2E-1E7990845E62Q28487743-BE5A1302-728D-4A92-AD83-792B8D943847Q28742668-4BBBFDE5-314E-4EEF-8001-DDD2D17109C9Q33477869-5221E680-E3BA-4FA6-B4F5-721BA549A26DQ33587558-445747BA-0888-4279-B260-D7CF20619FD2Q33980259-E3C42B6D-0BFD-463B-870E-C53EFD2E2E32Q35781537-C0B8648C-6173-452C-ACC0-170E56EA5F1CQ35813841-364EC6F3-3F77-4A8B-A212-EE1F03E93AF3Q35911656-5FAA5006-5219-43C8-8616-B605FE18313CQ36994177-ECC95A65-5938-48F0-A776-A308F3D225B0Q36999167-3C1B5719-51A2-4015-8A5B-309A614B028DQ37191213-C8404CDF-B183-4388-A9DF-887D5F89285CQ37603607-79929EE1-E5DF-4E5C-AD3E-164ECC19618FQ37771370-10FE8303-656E-4389-96A7-D6039E1FE7DFQ38016511-D3B0A1C7-2A9B-4A8E-B8BE-43AD58C839E2Q39305333-CD15070C-A8C2-4F80-ADFA-D64BB74930C3Q55365628-E91356DB-7DFA-4E9D-9473-91DD0A30BD2D
P2860
Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Antitumour and antiangiogenic ...... eic models of multiple myeloma
@en
Antitumour and antiangiogenic ...... ic models of multiple myeloma.
@nl
type
label
Antitumour and antiangiogenic ...... eic models of multiple myeloma
@en
Antitumour and antiangiogenic ...... ic models of multiple myeloma.
@nl
prefLabel
Antitumour and antiangiogenic ...... eic models of multiple myeloma
@en
Antitumour and antiangiogenic ...... ic models of multiple myeloma.
@nl
P2093
P2860
P356
P1476
Antitumour and antiangiogenic ...... eic models of multiple myeloma
@en
P2093
B Van Camp
E Van Valckenborgh
H De Raeve
K Vanderkerken
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604388
P407
P577
2008-06-03T00:00:00Z